Introduction

Sudden cardiac death (SCD) is one of the most devastating outcomes in cardiovascular medicine, accounting for around 4–5 million deaths per year.¹ SCD is an unexpected death caused by a sudden loss of heart function, typically within an hour, due to the dysfunction of the heart.² Furthermore, this fatality can affect anyone, regardless of whether heart disease was previously identified. This concerning number underscores the paramount importance of early intervention.

Left bundle branch block (LBBB) is a heart condition where the electrical signal to the left ventricle is delayed, causing it to contract later than normal.³ LBBB can occur in healthy individuals; however, it is commonly associated with different cardiomyopathies and hypertension. These conditions can significantly increase the likelihood of developing LBBB and hence increase the risk of SCD.

Recent studies suggest that patients with LBBB are at heightened risk of SCD. Hence, this essay will explore the evidence supporting this hypothesis, alongside discussing how to approach the management and mitigation of LBBB and SCD.

Understanding Left Bundle Branch Block

Before diving into the risks of SCD caused by LBBB, it is important to understand how the normal cardiac conduction system works, and then how LBBB is caused. The heart is myogenic, meaning that the muscle generates its own electrical impulse. It first originates from the sinoatrial node (SAN) in the right atrium. This signal then moves to the atrioventricular node (AVN), at which point a small delay occurs to allow the atria time to fully contract and relax. Finally, it passes through the His-Purkinje system, also known as the 'bundle of His', where the signal divides into the left and right bundle branches. These bundle branches make sure that the depolarisation is synchronous so the ventricles can contract at the same time.⁴

Unfortunately, in left bundle branch block, as the name suggests, the left bundle branch (LBB) is delayed or, in some cases, almost completely blocked. Hence, the contraction of both ventricles is asynchronous (ventricular dyssynchrony). This reduces cardiac output due to a decreased stroke volume, increases wall stress, lowers overall cardiac efficiency, and raises the potential to develop a ventricular arrhythmia. On an electrocardiogram (ECG), LBBB can manifest as a widened QRS complex, with broad or notched R waves in the lateral leads and deep S waves in the precordial leads.⁵

The incidence and prevalence of LBBB vary across different populations based on factors such as age, race, sex, and underlying cardiovascular conditions. LBBB is prevalent in about 0.06% to 0.1% of the general population. In individuals older than 70, the prevalence can be as high as 1% to 5%. The prevalence further increases in people older than 80, with some studies reporting rates as high as 6% to 7%.⁶

Sudden Cardiac Death: Definition and Mechanisms

Unlike chronic heart failure or progressive myocardial dysfunction, SCD is abrupt and often fatal, accounting for 15–20% of all deaths worldwide.⁷ There are several mechanisms underlying SCD. One of the most common and immediate causes is ventricular tachyarrhythmias. These include ventricular tachycardia and ventricular fibrillation.⁸ In short, these cause the ventricles to contract rapidly (ventricular tachycardia) and irregularly (ventricular fibrillation).⁹ SCD can also result from acute myocardial ischaemia (for instance, as a result of atherosclerosis) or electromechanical dissociation.¹⁰

Some categories of factors that may contribute to ventricular tachyarrhythmias include:

Structural Abnormalities

• Myocardial fibrosis (formation of scar tissue) and infarcted tissue (from a previous heart attack) create areas where electrical signals move unevenly
• Ventricular dilatation (enlarged heart chambers) stretches the heart muscle, also disrupting normal electrical conduction

Electrophysiological Disturbances

• Autonomic tone alterations (changes in nervous system control) can speed up or destabilise the heart rhythm
• Electrolyte imbalances (such as low potassium or calcium) make the heart more excitable and prone to arrhythmias
• Genetic predispositions can affect ion channels or other electrical properties of the heart, increasing arrhythmia risk

Underlying Heart Disease

• Conditions such as coronary artery disease (CAD), any cardiomyopathy (disease of the heart muscle), or left ventricular dysfunction further increase vulnerability to ventricular tachyarrhythmias because the heart is already weakened or scarred

Pathophysiological Link Between LBBB and SCD

As aforementioned, the left ventricle contracts later than the right. These patches of altered electrical conduction can allow abnormal circuits called re-entrant circuits to form. A re-entrant circuit occurs when the electrical impulse loops back on itself instead of dying out, repeatedly activating the same area of the heart. This suggests that LBBB alone can be a potential cause of ventricular tachyarrhythmia.

Additionally, LBBB is seen quite commonly in people with structural heart disease. One of the most well-recognised is ischaemic cardiomyopathy, which is heart muscle damage caused by reduced blood supply, or dilated cardiomyopathy, characterised by enlarged and weakened chambers. When a patient has ischaemic cardiomyopathy, there is an increased risk of electrical disturbances in the myocardium. This is because the myocardium can become scarred, and scar tissue does not conduct electricity normally. Additionally, in dilated cardiomyopathy, there is also cardiac remodelling, which could mean that the impulses have longer paths to travel. The combination of a structural heart condition and LBBB can cause these factors to accumulate, increasing the likelihood of life-threatening arrhythmic events.¹¹

Another important factor is that LBBB can influence patterns of repolarisation (the 'reset' period of electrical activity within the heart muscle) across the ventricles. Abnormal repolarisation contributes to electrical instability, further predisposing the heart to potentially fatal arrhythmias. Patients with LBBB who also have reduced left ventricular ejection fraction (LVEF) are particularly vulnerable, as the combination of structural disease, electrical delay, and mechanical dyssynchrony creates a high-risk environment for sudden cardiac death.

In essence, LBBB is not only an electrocardiographic anomaly; it represents a marker of underlying cardiac disease and a mechanistic contributor to the electrical and mechanical conditions that can precipitate sudden cardiac death.

Clinical Evidence and Epidemiological Data

Several studies have examined how the presence of left bundle branch block (LBBB) relates to cardiovascular outcomes, including the risk of sudden cardiac death (SCD). Among patients with established heart failure, data indicate a strong independent association. For example, in a registry of 5,517 out-patients with congestive heart failure (CHF) of various causes (ischaemic heart disease, dilated cardiomyopathy and hypertensive heart disease), LBBB was present in 25.2% of patients. After adjusting for age, heart-failure severity and prescription of ACE-inhibitors and beta-blockers, LBBB remained significantly associated with greater one-year all-cause mortality (hazard ratio 1.70; 95% CI 1.41–2.05) and sudden death (hazard ratio 1.58; 95% CI 1.21–2.06).¹²

In community-based populations without overt heart failure or myocardial infarction, LBBB has also been shown to predict future adverse outcomes. A cohort of older adults (mean age ~72.6 years) with structurally normal hearts found that baseline LBBB was independently associated with incident heart failure (HR 4.98; 95% CI 2.18–11.39) and with decline in left ventricular ejection fraction over 5 years.¹³

Furthermore, among hypertensive patients with left ventricular hypertrophy but no baseline LBBB, the development of new (incident) LBBB predicted a higher risk of cardiovascular death, heart failure and all-cause mortality (for example, HR ~3.0 for CV death in one study).¹⁴

Although direct large-scale prospective data linking LBBB specifically to SCD (rather than more general cardiovascular death) remain more limited, these investigations support the view that LBBB is more than a benign ECG finding. Rather, it frequently signals elevated risk, particularly when structural heart disease, reduced ejection fraction or other comorbidities are present.

However, several caveats should be noted: many of these studies involve mixed populations with different underlying heart diseases; definitions of LBBB and durations of follow-up vary; and it remains difficult to isolate the independent effect of LBBB on SCD risk versus its association with underlying cardiomyopathy or ischaemic disease.

Management and Preventive Strategies

The management of patients with LBBB should be chosen holistically, addressing both the underlying heart disease and SCD. Cardiac resynchronisation therapy (CRT) is a cornerstone intervention in patients with LBBB. CRT not only treats LBBB but also heart failure when the left ventricular ejection fraction (LVEF) is reduced, i.e., less than 35%, alongside a QRS duration longer than 130ms. Furthermore, according to the 2022 American College of Cardiology guideline, CRT is indicated to reduce total mortality and hospitalisations and to improve symptoms in patients with a specific presentation of the disease (NYHA class II-III), including lack of arrhythmia, lowered ejection fraction, and ongoing medical therapy.¹⁵

Another major management strategy is implantable cardioverter-defibrillators (ICDs); these are recommended for primary or secondary prevention of SCD in high-risk patients. For example, in patients with heart failure with reduced ejection fraction (HFrEF), symptomatic NYHA class II–III, and LVEF below 35% despite more than 3 months of optimal medical therapy, an ICD is recommended to reduce the risk of SCD.¹⁶ Decision-making regarding ICD implantation should take into account LVEF, symptom burden, comorbidities, and life expectancy.

Finally, pharmacological intervention is also an important management strategy. Medications including beta-blockers, ACE inhibitors, angiotensin receptor–neprilysin inhibitors (ARNIs), mineralocorticoid-receptor antagonists (also known as aldosterone antagonists), and SGLT2 inhibitors can improve ventricular function, reduce arrhythmic risk, and improve survival. These therapies are particularly important in patients with heart failure and LBBB, as they address the underlying myocardial disease, which contributes to both conduction abnormalities and risk of arrhythmias.

Emerging strategies focus on early identification and risk stratification, using modalities such as advanced cardiac imaging to detect fibrosis or conduction abnormalities, genetic testing in selected cases, and advanced ECG analysis to predict arrhythmic risk. Lifestyle optimisation and management of comorbidities (such as hypertension, diabetes, and coronary artery disease) also play an important role in reducing overall cardiovascular risk.

Summary

In summary, left bundle branch block (LBBB) can be an important warning sign of underlying heart problems and an increased risk of serious adverse events, including sudden cardiac death. Evaluating heart structure and function is crucial in identifying patients who may benefit from treatments such as cardiac resynchronisation therapy (CRT), implantable cardioverter-defibrillators (ICDs), and optimised medications to support heart function. Using tools such as imaging, heart rhythm monitoring, and other diagnostic technologies allows clinicians to personalise care and monitor high-risk patients more closely.

Early recognition of LBBB provides the opportunity to implement targeted interventions, improve cardiac efficiency, reduce arrhythmic risk, and ultimately enhance long-term heart health and chance of survival.